Expanded Access Programs

We are committed to bringing new investigational medicines to patients with serious diseases as quickly and efficiently as possible. Arrowhead’s expanded access to investigational medicines is a means by which investigational medicines are made available, under certain circumstances, to treat patients with serious diseases who are ineligible or unable to participate in an ongoing Arrowhead clinical trial. As with any investigational medicine that has not been approved by regulatory authorities, the investigational medicine may or may not be effective in treating your diagnosis or condition, and there may be risks associated with its use. If you are a patient interested in participating, you should talk to your physician about the potential benefits and risks of taking part in the expanded access to an investigational medicine. To learn more about access to investigational medicines at Arrowhead, review our compassionate use agreement.

Plozasiran Expanded Access Program (EAP) for Familial Chylomicronemia Syndrome (FCS) Now Available

Plozasiran is an investigational medicine designed to reduce the production of the protein Apolipoprotein-CIII (ApoC3) through the natural RNA interference (RNAi) mechanism.  ApoC3 is a protein that is produced in liver cells and inhibits the formation and clearance of various lipids and lipoproteins, including triglycerides. Plozasiran is currently being investigated to determine whether it is safe and effective to reduce the level of ApoC3, thereby reducing triglycerides. The plozasiran EAP is for individuals living with familial chylomicronemia syndrome (FCS).

If you are a patient or caregiver wishing to know more about this plozasiran EAP for FCS, please discuss this EAP and all treatment options with your treating physician. If you are a treating physician and are seeking information about the plozasiran EAP or would like to request access for a patient, please contact EAP@arrowheadpharma.com.